STING1 and neoplasm: With reduced antigenicity, STING activation can induce tolerogenic immune responses and facilitate tumor progression; with enhanced antigenicity, STING activation can induce potent innate and adaptive anti-tumor immune responses via APCs and CD8+ T cells.